Amlessa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amlessa

Property Description
Active Ingredient Amlodipine, Perindopril
Form Fixed-dose combination tablets
Pharmacological Class Antihypertensive agents (ACE inhibitor + CCB)
Common Use Management of essential hypertension
Origin Synthetic chemical compounds

What Type of Medicine is Amlessa?

Amlessa is a single-pill, fixed-dose combination (FDC) formulated as a tablet for oral administration, and is classified as an antihypertensive agent. The combination integrates two distinct blood pressure-lowering compounds into one unit, a design that is clinically recognized for supporting patient adherence to their prescribed regimen. This synthetic medicinal entity simplifies the therapeutic approach by providing the benefits of two pharmacological classes in a single daily dose, a key differentiating factor from using two separate tablets.

Composition: The Dual Synthetic Active Ingredients

The core of Amlessa is its dual composition of the International Nonproprietary Names (INN) Amlodipine and Perindopril, both of synthetic chemical origin. Amlodipine is specifically classified as a Calcium Channel Blocker (CCB), which acts to prevent the influx of calcium ions necessary for blood vessel contraction. Perindopril is an Angiotensin-Converting Enzyme (ACE) inhibitor, which interferes with the enzyme responsible for creating a powerful vasoconstricting hormone. This pairing is widely known internationally, with similar formulations sometimes marketed under other brands, such as Prestalia.

Primary General Purpose (Dual Action Benefit)

The primary general purpose of Amlessa is the effective and sustained management of essential hypertension by delivering a complementary, dual-action benefit. The component actions—Amlodipine's vessel wall relaxation and Perindopril's reduction of the body's pressure-generating system—results in widespread vasodilation and a significant decrease in peripheral vascular resistance. A typical use scenario involves a patient who has not achieved adequate pressure control with a single agent and requires the established efficacy of this ACE inhibitor and CCB combination. This comprehensive physiological effect is beneficial for individuals seeking normalized blood pressure control.

Regulatory References

  1. Amlodipine
  2. Perindopril
  3. essential hypertension
  4. EMA (Amlodipine)

What side effects are possible with Amlessa?

Possible Side Effects and Safety Information

The safety profile for Amlessa, a fixed-dose combination of an ACE inhibitor (Perindopril) and a calcium channel blocker (Amlodipine), is officially classified by regulatory authorities based on the frequency and physiological system affected.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on their statistical occurrence in clinical trials, separating common effects from rare, serious reactions documented in official prescribing information.

Frequency Term Associated Common Effects (Selected)
Very Common (ge 1/10) Peripheral oedema (swelling)
Common (ge 1/100 to < 1/10) Headache, dizziness, cough, fatigue, flushing
Uncommon (ge 1/1,000 to < 1/100) Syncope (fainting), palpitations, rash, renal impairment

The characteristic cough associated with the ACE inhibitor class is listed as Common.


Serious Adverse Reactions and Key Constraints

Serious adverse reactions, though classified as Very Rare (< 1/10,000), include potentially life-threatening conditions such as angioedema (swelling of the face, limbs, or throat) and severe liver or pancreatic inflammation (hepatitis, pancreatitis). Myocardial infarction or stroke may occur secondary to excessive low blood pressure (hypotension) in vulnerable patients.

Key safety constraints formally established in regulatory documents include a contraindication for use during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Use is also restricted in patients with a history of angioedema related to prior ACE inhibitor therapy. The official profile notes that effects such as dizziness and hypotension are more likely to occur at the start of treatment or following dose adjustments.

Monitoring and caution are specifically required for individuals with pre-existing conditions, including renal or hepatic impairment, as the clearance of the medicine's components may be affected.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Amlessa (Amlodipine/Perindopril) primarily in terms of severe cardiovascular compromise. Immediate medical attention must be sought for any suspected overdose.

Property Documented Overdose Manifestations
Documented Presentations Severe and prolonged hypotension is the most significant clinical sign, which may be accompanied by reflex tachycardia or bradycardia. Neurological effects may include dizziness, somnolence, and confusion.
Severe Outcomes The risks include progression to profound shock and organ hypoperfusion. In high-risk patients, an excessive fall in blood pressure may lead to myocardial infarction or cerebrovascular accident.
Laboratory/System Effects The Perindopril component carries a documented risk of Hyperkalemia (elevated serum potassium) and potential acute renal failure secondary to prolonged hypotension.

Required Emergency Action

The regulatory standard is to initiate prompt symptomatic and supportive treatment. Due to the long half-life of amlodipine, prolonged monitoring is often necessary. Management includes placing the individual in the supine position, administering intravenous fluid resuscitation, and providing pressor support if required. No specific antidote is known for this combination overdose. Patients with hepatic impairment may experience reduced drug clearance, potentially prolonging the toxic effects.

Therapeutic Uses of Amlessa

What Amlessa Treats: Main Uses and Benefits

Amlessa is applied across therapeutic domains where supportive management of high blood pressure is needed. This dual-agent medication is generally used as substitution therapy for the treatment of Essential Hypertension and/or Stable Coronary Artery Disease in patients whose conditions are already well-controlled with the individual components. The medication is relevant for easing symptoms related to systemic imbalance, which are common in conditions marked by increased physiological stress.

Sustained Management and Risk Support

Essential Hypertension is commonly used for managing the symptoms related to systemic imbalance associated with Essential Hypertension. This use is considered relevant for easing symptoms that create noticeable physiological strain and supports the maintenance of functional stability during symptomatic periods. The primary benefit may assist with maintaining a sense of stability when symptoms are more noticeable, by supporting blood pressure targets. The single-pill format assists with maintaining functional stability by contributing to improved adherence to the multi-drug regimen.

“The single-pill approach assists with maintaining functional stability by helping patients cope more steadily with the complexity of long-term medication schedules.”

The main indications covered include Essential Hypertension, the long-term management of cardiovascular risk factors, and use as substitution therapy for Stable Coronary Artery Disease.


Quick Fact: Relief for Systemic Imbalance

Amlessa is applied in clinical settings that involve chronic, unstable symptom patterns, supporting the overall management of persistently high arterial pressure, and assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Amlessa (Perindopril/Amlodipine) eligibility is strictly defined by regulatory authorities and is generally restricted to Adults (ge 18 years) for established uses like essential hypertension and stable coronary artery disease. The fixed-dose combination is specifically used as substitution therapy for patients already stabilized on the individual components.


Official Regulatory Exclusions (Contraindications)

Use is absolutely prohibited for patients meeting the following official criteria:

  • Hypersensitivity: Allergy to perindopril, amlodipine, or any other ACE inhibitor or dihydropyridine derivative.
  • Angioedema History: Prior angioedema linked to any ACE inhibitor treatment.
  • Pregnancy: During the second and third trimesters (use is also not recommended in the first trimester).
  • Cardiovascular Conditions: Severe hypotension, cardiogenic shock, or obstruction of the left ventricle outflow tract (e.g., aortic stenosis).

Population-Specific Limitations

Population / Condition Regulatory Status Restriction Basis
Children & Adolescents ( under 18 years) Not Recommended Efficacy and safety have not been established.
Severe Renal/Hepatic Impairment Not Recommended Use is constrained by impaired organ function.
Lactation (Breastfeeding) Not Recommended Risk to the infant is unknown; cessation is required.
Specific Combination Use Contraindicated Concurrent use with Aliskiren (in specific patients) or Sacubitril/Valsartan.

What should I know about interactions with other medicines?

Amlessa (amlodipine/perindopril) has officially documented interactions with other medicines and products, which are outlined in regulatory labeling. Certain combinations are classified as contraindicated.

Formally Documented Contraindications

  • Sacubitril/valsartan: Co-administration is prohibited. The medicine must not be started earlier than 36 hours after the last dose of sacubitril/valsartan, or vice versa.
  • Aliskiren-containing products: The combination is contraindicated in patients with diabetes mellitus or those with renal impairment (GFR below 60 mL/min/1.73 m^2).

Other Significant Interactions

Co-administration with strong or moderate CYP3A4 inhibitors (e.g., clarithromycin, diltiazem) is documented to cause a significant increase in amlodipine exposure.

Pharmacodynamic interactions can occur with several substance categories:

  • Potassium-sparing diuretics and potassium supplements increase the risk of hyperkalemia (elevated serum potassium levels).
  • NSAIDs may increase the risk of renal function deterioration and can diminish the blood pressure-lowering effect.
  • mTOR inhibitors (e.g., sirolimus, everolimus) are associated with an increased risk for angioedema.

Regarding non-medicinal substances, consumption of grapefruit or grapefruit juice is not recommended due to its potential to increase amlodipine bioavailability.

Mechanism of Action

How Amlessa Works: The Dual Mechanism of Action

The mechanism involves the simultaneous action of two independent pharmacodynamic components: the direct modulation of vascular tone and the suppression of a key hormonal pressure-regulating system. This coordinated action results in a physiological adjustment to circulatory resistance and volume.


Direct Blockade of Vascular Calcium Channels

This core mechanism involves the Amlodipine component, a calcium channel blocker that directly acts on voltage-dependent L-type calcium channels in the walls of resistance arterioles. The drug blocks the influx of Ca^2+ ions required for muscle contraction, leading to relaxation of the arterial smooth muscle. This action decreases systemic arterial resistance (afterload), influencing overall vascular tone.


Suppression of the Renin-Angiotensin-Aldosterone System (RAAS)

The second key mechanism is mediated by Perindopril, an ACE inhibitor, which acts to inhibit the enzyme responsible for converting Angiotensin I into the potent vasoconstrictor, Angiotensin II. By suppressing ACE, the drug limits the production of Angiotensin II and, consequently, reduces the secretion of the volume-regulating hormone Aldosterone. This modulation of the RAAS decreases both hormonal vasoconstriction and the retention of sodium and water, influencing volume homeostasis.


Mechanistic Synergy and Afterload Influence

The two domains operate on distinct but complementary pathways: one targets the structural contractility of the arteries, and the other targets the humoral regulators of pressure and volume. This synergistic effect influences peripheral vascular resistance and creates a reduced pressure load on the cardiovascular system.

Dosage and Administration Information

The Amlessa fixed-dose combination (Perindopril/Amlodipine) is for oral administration as a single tablet once daily. Precise conditions are established for administration, frequency, and dosage adjustment, structuring its use for chronic management.

The medicine is typically taken once a day, preferably in the morning and before a meal, to ensure consistent daily absorption.

Treatment initiation generally starts with the lowest available strength, such as the 3.5 mg/2.5 mg combination. Subsequent dosage adjustments must be separated by a required interval of 7 to 14 days to allow for assessment before reaching the maximum recommended daily dose of 14 mg/10 mg. This formalized titration schedule defines the appropriate procedural structure for long-term administration.

Specific dosage constraints exist for certain populations. The maximum dose is restricted to 7 mg/5 mg daily for individuals with mild to moderate renal impairment, and the medicine is generally not recommended in cases of severe renal dysfunction. Use in the pediatric population (under 18 years of age) is also not established and is not recommended. If a scheduled dose is missed, the dose must be skipped entirely, and the user must not take a double dose, continuing instead with the next regular scheduled dose. These guidelines collectively define the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amlessa

Evidence for Use in Essential Hypertension

The clinical evaluation of the Amlodipine/Perindopril fixed-dose combination (FDC) for Essential Hypertension rests primarily on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials were conducted to evaluate the combination's effect on high blood pressure measurements, including changes in office blood pressure and 24-hour readings. Studies also explored whether the combination was applied in studies exploring the management of blood pressure in people with co-existing conditions, such as diabetes.

Studies reported measurements observed during the trial period where the combination therapy was associated with changes in blood pressure readings. Findings indicated that studies observed different rates of achieving blood pressure goals when using the combination compared to using a single drug alone. Longer-term observational studies monitored patients in real-world settings to examine medication adherence, describing patterns where patients using the single fixed-dose pill were observed to have different rates of long-term treatment persistence compared to patients who took the two medicines as separate tablets.


Evidence for Use as Substitution Therapy in Stable Coronary Artery Disease

Research exploring the use of the FDC in patients with Stable Coronary Artery Disease (SCAD) primarily includes studies focusing on its application as a substitution therapy. This research concentrated on patients whose condition was already considered stable and well-controlled while taking the two individual medications separately. The evidence also stems from post-hoc and subgroup analyses of large cardiovascular outcome trials that used the individual component medicines.

The studies monitored blood pressure changes and measured patient functional status, describing the patterns observed in the study populations over the defined period. Substitution trials reported that the fixed-dose combination could be used to maintain blood pressure control in patients previously managed with the separate tablets. However, comparative evidence is lacking, and dedicated studies with long follow-up durations focusing specifically on the FDC are not widely available.


What Remains Uncertain in the Research Landscape

Evidence concerning long-term effects on clinical outcomes, such as the incidence of stroke or heart attack, is often extrapolated from the component medicines rather than the FDC itself. Research consensus indicates limited certainty for conclusions beyond the established evidence of the individual component drugs. Evidence quality varies across studies, and some long-term data for the combination is observational, which can introduce uncertainties.

Key Studies & References

  1. Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review
  2. EMA Public Assessment Report Scientific discussion Perindopril tert‐butylamine/Amlodipine Denk (Relevant to FDC regulatory assessment)

Frequently Asked Questions (FAQ)

Common questions about Amlessa (FAQ)


Q: Can Amlessa cause a persistent dry cough?

Official product information states that a cough is a common side effect of the perindopril component. This cough is typically described as persistent and nonproductive, meaning it is dry. Official documents describe the cough as typically resolving after discontinuation of therapy.

Q: Can Amlessa be taken with common pain relievers like ibuprofen?

Regulatory documents indicate that combining this medicine with nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may reduce its blood pressure-lowering effect. This combination may also increase the risk of temporary kidney function deterioration.

Q: Does Amlessa interact with supplements like potassium or herbal remedies?

Official warnings state that potassium supplements or potassium-sparing diuretics may increase the risk of hyperkalemia (high potassium levels). There is generally insufficient information on combining the drug with many herbal remedies, and regulatory documents indicate that caution is needed with untested herbal remedies.

Q: Does Amlessa interact with common cold or flu medications?

Many common cold and flu medications contain ingredients like sympathomimetic agents. These agents can raise blood pressure and heart rate, potentially causing adverse cardiovascular effects. Use of such medications is described as requiring caution while taking blood pressure medicine.

Q: Is it normal to feel dizzy when standing up after taking Amlessa?

Dizziness is listed as a common side effect of the medicine. Official patient guidance notes that lightheadedness is more likely to occur when standing up quickly. This feeling is related to a temporary drop in blood pressure known as orthostatic hypotension.

Q: What are the most common things people feel when they first start taking Amlessa?

The most common effects reported in clinical studies include swelling of the ankles or feet (peripheral oedema), headache, dizziness, fatigue, and cough. Official information notes that dizziness and low blood pressure are more likely to occur when first starting treatment or after a change in dosage.

Q: What is Amlessa used for, besides high blood pressure?

In addition to treating essential hypertension (high blood pressure), regulatory documents indicate that the medicine is used for people with stable coronary artery disease (SCAD). This use is specifically for substitution therapy in patients whose condition is already controlled while taking the two active components separately.

Q: How quickly should I expect to see effects after starting Amlessa?

Official pharmacological data for the amlodipine component shows it reaches its highest concentration in the blood within 6 to 12 hours after an oral dose. Since the drug is taken once daily, its effect is designed to last for at least 24 hours.

Q: Does Amlessa cause weight gain or weight loss?

Regulatory product information lists both weight gain and weight decrease as uncommon side effects. Swelling of the limbs (peripheral oedema), which is a very common side effect, may also contribute to a change in weight.

Q: How long does the effect of one tablet of Amlessa last in the body?

The effect of one tablet is designed to last for at least 24 hours to support once-daily dosing. The amlodipine component has a long elimination half-life, which means it takes 30 to 50 hours for half the drug to be cleared from the body.

Q: Are there any serious side effects associated with Amlessa that I should know about?

Regulatory sources document serious adverse reactions, which, though rare, include angioedema (severe swelling of the face or throat). Other serious concerns include severe liver or pancreatic inflammation. Extremely low blood pressure (hypotension) could also lead to conditions like myocardial infarction or stroke in susceptible patients.

Q: Does Amlessa have a risk of affecting kidney function?

The perindopril component is associated with a risk of affecting kidney function, especially in individuals with pre-existing impaired renal blood flow. Official safety information notes that monitoring of kidney function markers like serum creatinine and potassium levels is frequently required.

Q: Can Amlessa be prescribed for people who have both high blood pressure and diabetes?

Regulatory documents state that the medicine is contraindicated only for patients with diabetes who are simultaneously taking aliskiren-containing products. Official warnings also note that ACE inhibitors may increase the blood-glucose lowering effect of antidiabetic medicines, which carries a risk of hypoglycemia.

Q: Can Amlessa be taken if I am lactose intolerant?

Official regulatory product information lists lactose as one of the inactive ingredients, or excipients, used in the manufacturing of the tablets.

Q: How often do people typically need blood tests while taking Amlessa?

Official guidelines note that frequent monitoring of serum creatinine and potassium levels is needed for patient follow-up. This monitoring is considered especially important for individuals who are elderly or who have pre-existing kidney impairment.

Q: Does Amlessa affect sleep patterns or cause insomnia?

Insomnia is not listed as a common side effect in regulatory documents. However, other nervous system effects such as drowsiness (somnolence) are reported as uncommon, and rare effects like confusion are also documented.

Q: Is it okay to drink alcohol in moderation while taking Amlessa?

Official information indicates that alcohol consumption may amplify the medicine's blood pressure-lowering effect. This can increase the risk of side effects such as dizziness, lightheadedness, headache, and fainting.

Q: What type of research evidence supports the use of Amlessa?

The drug's use is supported by the findings of short-term Randomized Controlled Trials (RCTs) for hypertension. It is also backed by studies focused on its use as substitution therapy for patients with stable coronary artery disease (SCAD).

Q: Is there any risk of rebound hypertension if I stop taking Amlessa suddenly?

Regulatory guidance on stopping high blood pressure medications suggests that abrupt cessation of some drugs can cause a rapid increase in blood pressure, known as rebound hypertension. Regulatory documents note that cessation of blood pressure medication is generally managed under medical supervision due to the potential for a rapid increase in blood pressure.

Q: Can Amlessa be taken by people with asthma or lung conditions?

There is no general regulatory contraindication for using this medicine in patients with uncomplicated asthma or lung conditions alone. However, caution is advised when co-administering the drug with certain pain relievers (NSAIDs) in individuals with pre-existing asthma.

Q: Can Amlessa affect mood or cause anxiety?

Official product information documents list psychiatric and nervous system effects as potential, though often rare, side effects. These documented effects include confusion and agitation.

Q: Are skin rashes a reported side effect of Amlessa?

Yes, skin rash is officially documented in regulatory sources as an uncommon side effect. This is a separate reaction from the more severe allergic swelling known as angioedema.

Q: What are the commonly reported gastrointestinal side effects of Amlessa?

Common gastrointestinal side effects reported in clinical trials include abdominal pain, nausea, vomiting, constipation, and diarrhea. Indigestion (dyspepsia) is also listed among the frequently reported adverse reactions.

Q: Is Amlessa's use supported by large-scale clinical trials?

Regulatory summaries indicate that the evidence for the fixed-dose combination (FDC) is based primarily on short-term Randomized Controlled Trials (RCTs). Long-term evidence concerning major clinical outcomes is often extrapolated from studies of the individual component medicines rather than the FDC itself.

Q: Does Amlessa prevent stroke or heart attack?

Official documents note that evidence concerning long-term effects on major clinical outcomes, such as the incidence of stroke or heart attack, is often extrapolated. This evidence is derived from studies of the individual component medicines, rather than from dedicated long-term studies focusing specifically on the fixed-dose combination itself.

Q: Does Amlessa require a prescription, or is it available over the counter?

Amlessa is a prescription medicine. It is not available for purchase over the counter and can only be dispensed with a valid doctor's prescription.

How should Amlessa be stored and disposed of?

Storage and Disposal of Amlessa

Official regulatory labeling defines specific storage constraints for Amlessa (perindopril/amlodipine) to ensure product stability and safety.

Storage Requirements

Constraint Requirement
Temperature Store below 30 C (or 25 C), and keep from freezing.
Container Must be kept in the original container and stored tightly closed.
Protection Store away from excessive heat, moisture, and direct light.
Child Safety Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Amlessa must be disposed of in accordance with local requirements for pharmaceutical waste. Disposal should prioritize official drug take-back programs, as the medicine should not be flushed down the toilet or thrown into household waste without proper preparation (mixing with an unappealing substance and sealing).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amlessa found in:

A-Z Index: